Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function
A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney function as it does in those with normal kidney function.